Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05192486
Other study ID # GNC-038-102
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 10, 2022
Est. completion date August 2024

Study information

Verified date April 2024
Source Sichuan Baili Pharmaceutical Co., Ltd.
Contact Hai Zhu
Phone +86-13980051002
Email zhuhai@baili-pharm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. he participants could understand and sign the informed consent form, and must participate voluntarily; 2. No gender limit; 3. Age: =18 years old and =75 years; 4. Expected survival time = 3 months; 5. Has suffered from Diffuse Large B-cell lymphoma (DLBCL) confirmed by histology or cytology; 6. a. Those who have recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL). b. Recurrent or refractory participants that are, determined by the investigators, not applicable/tolerated to other treatments. Recurrent and refractory are defined as follows: Recurrent is the progression of disease after adequate treatment to remission, with at least one regimen containing rituximab. Refractory refers to failure to respond to adequate treatment with rituximab containing regimen (combination chemotherapy or monotherapy) or disease progression during treatment/within 6 months of completion of adequate treatment. "Adequate treatment with rituximab regimen" refers to the completion of rituximab combined with chemotherapy based on pathological type and disease stage requirements, or rituximab monotherapy with 375 mg/m2 injections at least 4 times a week. "Progress during treatment" requires completion of at least one cycle of rituximab plus chemotherapy or monotherapy if progress during induction therapy; At least one injection is completed if progress is made during maintenance therapy. "Mitigation" includes complete and partial mitigation. 7. There are measurable lesions during the screening period (any long diameter of lymph node lesions = 1.5 cm or any long diameter of extra-nodal lesions greater than 1.0 cm); 8. Physical fitness score ECOG=2; 9. The toxicity of the previous anti-tumor therapy has been restored to the level =1 defined by NCI-CTCAE v5.0 (the investigators considered indicators that might be associated with the disease, such as anemia, and excluded toxicities that the investigators considered to be of no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy); 10. The organ function within 7 days prior to the first administration meets the following requirements: - Bone marrow function: In the case of no blood transfusion, no use of G-CSF (no use of long-acting whitening needles within 2 weeks) and drug correction within 7 days prior to screening, the absolute value of neutrophil count (ANC) =1.0×109/L (participants with bone marrow infiltration =0.5×109/L); Hemoglobin =80 g/L (for participants with bone marrow infiltration, =70 g/L); Platelet count =50×109/L; - Liver function: In the absence of hepatoprotective drugs for correction within 7 days prior to screening, total bilirubin (TBIL) = 1.5 ULN (TBIL =3 ULN in participants with Gilbert's syndrome), transaminase (AST/ALT) = 2.5 ULN (participants with tumor infiltration in the liver =5.0 ULN); - Kidney function: creatinine (Cr) = 1.5 ULN and creatinine clearance (Ccr) = 50 mL/min (according to the Cockcroft and Gault formula); - Routine urine / 24h urine protein quantification: qualitative urine protein =1+ (if qualitative urine protein =2+, 24h urine protein < 1g can be included); - Cardiac function: left ventricular ejection fraction =50%; - Coagulation function: fibrinogen (FIB) =1.5g/L; activated partial thromboplastin time (APTT) =1.5×ULN; prothrombin time (PT) =1.5×ULN. 11. Female participants with fertility or male participants whose partner(s) are fertile must take effective contraceptive measures from 7 days prior to the first administration to 24 weeks after the administration. Female participants with fertility must have a negative serum/urine pregnancy test in 7 days prior to the first dose. 12. The subjects are able and willing to follow the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol. Exclusion Criteria: 1. Has grade 3 or above lung disease defined according to NCI-CTCAE v5.0; Patients with current interstitial lung disease (ILD) (except those who have recovered from previous interstitial pneumonia; 2. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc; 3. Active tuberculosis; 4. Participants at risk of active autoimmune diseases, such as: systemic lupus erythematosus, systemic treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and hashimoto's thyroiditis, etc., with the exception of type I diabetes, only replacement therapy can control the hypothyroidism, no systemic treatment of skin disease (such as vitiligo, psoriasis), B cells caused by autoimmune disease; 5. Complicated with other malignant tumors within 5 years prior to GNC-038 treatment, except for non-melanoma skin cancer in situ, superficial bladder cancer, cervical cancer in situ, gastrointestinal intramucosal cancer, breast cancer and localized prostate cancer that have been cured and have not recurred within 5 years; 6. HBsAg or HBcAb positive and HBV-DNA test =ULN; HCV antibody positive and HCV-RNA=ULN; HIV antibody positive; 7. Participants with poorly controlled hypertension by antihypertensive drugs (systolic blood pressure>150 mmHg or diastolic blood pressure>100 mmHg); 8. History of severe heart disease, including but not limited to: - There are serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias, III grade atrioventricular block, which require clinical intervention; - Participants with prolonged QT interval (male QTc > 450 msec or female QTc > 470 msec); - Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months before the first administration; - New York Heart Association (NYHA) grade II, III or IV congestive heart failure; 9. Patients with a history of allergy to recombinant humanized antibodies or to any excipient component of GNC-038; 10. Pregnant or breastfeeding women; 11. There is an invasion of the central nervous system; 12. Has undergone major surgery within 28 days prior to the administration of this study, or planned to undergo major surgery during the study period (except for surgery such as puncture or lymph node biopsy); 13. Has accepted organ transplantation or allogeneic hematopoietic stem cell transplantation (ALLo-HSCT); 14. Has accepted autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks prior to GNC-038 treatment; 15. Currently using immunosuppressive agents within 2 weeks prior to GNC-038 treatment, including but not limited to: Cyclosporine, tacrolimus, etc.; receiving high-dose glucocorticoids within 2 weeks prior to GNC-038 treatment (longer than 14 days, a stable dose of >30 mg of prednisone or other glucocorticoids at the same dose per day); 16. Has received radiotherapy within 4 weeks prior to GNC-038 treatment; 17. Has received anti-CD20 or anti-CD79b treatment within 4 weeks prior to GNC-038 treatment, and continued to respond; 18. Has received chemotherapy, small molecule targeted drugs within 2 weeks prior to GNC-038 treatment; 19. Has received CAR-T treatment within 12 weeks prior to GNC-038 treatment. 20. Has participated in any other clinical trials within 4 weeks prior to GNC-038 treatment; 21. Other conditions that the investigator believes that it is not suitable for participating in this clinical trial.

Study Design


Intervention

Drug:
GNC-038
Administration by intravenous infusion

Locations

Country Name City State
China Affiliated Hospital of Hebei University Baoding Hebei
China The First Affiliated Hospital of Henan University of Science and Technology Luoyang Henan
China Ruijin Hospital, Shanghai JiaoTong University School of Medicine Shanghai Shanghai
China Shenzhen Second People's Hospital Shenzhen Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Sichuan Baili Pharmaceutical Co., Ltd. SystImmune Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity (DLT) The incidence and severity of adverse events during treatment were graded according to the National Cancer Institute Standard for Common Terminology for Adverse Events (NCI-CTCAE, v5.0). Up to 21 days after the first dose of GNC-038
Primary Maximum tolerated dose (MTD) or maximum administrated dose (MAD) In the dose increment stage, the highest dose whose estimated DLT rate is closest to the target DLT rate but does not exceed the upper bound of the equivalent interval of DLT rate is selected as MTD. Up to 21 days after the first dose of GNC-038
Primary Treatment-Emergent Adverse Event (TEAE) TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-038. The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-038. Up to approximately 24 months
Primary The recommended dose for phase II clinical study(RP2D) The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-038. Up to 21 days after the first dose of GNC-038
Secondary ORR (Objective Response Rate ) ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1. Up to approximately 24 months
Secondary PFS (Progression-free Survival) The PFS is defined as the time from the participant's first dose of GNC-038 to the first date of either disease progression or death, whichever occurs first. Up to approximately 24 months
Secondary DCR (Disease Control Rate) The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD]). Up to approximately 24 months
Secondary DOR (Duration of Response) The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first. Up to approximately 24 months
Secondary CR (Complete Response) Disappearance of all target lesions. Up to approximately 24 months
Secondary Adverse Events of special interest (AESI) AESI is an event of scientific and medical interest specific to the sponsor's product or research project. Up to approximately 24 months
Secondary Peak Plasma Concentration(Cmax) Maximum serum concentration (Cmax) of GNC-038 will be investigated. Up to 21 days after the first dose of GNC-038
Secondary Incidence and titer of ADA (Anti-drug antibody) Frequency and titer of anti-GNC-038 antibody (ADA) will be evaluated. Up to approximately 24 months
Secondary Incidence and titer of Nab Incidence and titer of Nab of GNC-038 will be evaluated. Up to approximately 24 months
Secondary Trough steady-state concentration(Css) Concentration of GNC-038 at steady state plateau will be investigated. Up to 14 days after the first dose of GNC-038
Secondary Time to reach maximum concentration (Tmax) Time to maximum serum concentration (Tmax) of GNC-038 will be investigated. Up to 21 days after the first dose of GNC-038
Secondary AUC0-inf Area under the plasma concentration-time curve from time 0 extrapolated to infinite (AUC0-inf). Up to 21 days after the first dose of GNC-038
Secondary AUC0-t Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration (AUC0-t). Up to 21 days after the first dose of GNC-038
Secondary Plasma clearance (CL) To study the serum clearance rate of GNC-038 per unit time. Up to 21 days after the first dose of GNC-038
Secondary Elimination half life (T1/2) Half-life (T1/2) of GNC-038 will be investigated. Up to 21 days after the first dose of GNC-038
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05823701 - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Phase 2
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT03656835 - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma N/A
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT02060656 - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Phase 2
Active, not recruiting NCT01653067 - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma Phase 2
Enrolling by invitation NCT00846157 - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Phase 3
Completed NCT00440583 - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Phase 2
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Recruiting NCT04981795 - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed NCT01186978 - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma N/A
Completed NCT01197560 - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase 2/Phase 3
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Not yet recruiting NCT05990985 - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. N/A
Completed NCT02890602 - Erythropoietin for Management of Anemia Caused by Chemotherapy Phase 2
Completed NCT03630159 - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Phase 1
Active, not recruiting NCT04529772 - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Phase 3
Active, not recruiting NCT02900651 - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT02481310 - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2